Nanomicellar preparation, HB-ATV-8, protects against endothelial dysfunction induced by a high-fat diet. Gutiérrez-Vidal R, Franco-Urquijo CA, Ríos-Rodríguez A, Escalante-Acosta B, Delgado-Coello B, Mas-Oliva J. Atherosclerosis 331:e60, 2021. doi: https://dx.doi.org/10.1016/j.atherosclerosis.2021.06.170
Mas-Oliva J. Molecular events involved in the efficacy of therapeutic vaccine HB-ATV-8. Atherosclerosis 315: 2020. doi: https://dx.doi.org/10.1016/j.atherosclerosis.2020.10.426
Novel intranasal anti-CETP vaccine against the development of atherosclerosis and fatty liver disease. Mas-Oliva J, Delgado-Coello B, Méndez-Acevedo K. European Atherosclerosis Society (EAS) 16-0745. Workshop 3.1: Novel therapies. Atherosclerosis 252:e238, 2016. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2016.07.020
Preclinical evidence studying intranasal HB-ATV-8 vaccines in a porcine model of atherosclerosis shows high efficiency in the prevention of atherogenesis and fatty liver disease. Mas-Oliva J, Delgado-Coello B, Méndez-Acevedo KM, Gutiérrez-Vidal R, and Calixto-Tlacomulco S. 85th European Atherosclerosis Society (EAS). Atherosclerosis 263:e52, 2017. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2017.06.177
The process of septic shock is attenuated by the intravenous administration of peptide VSAK: a FDG-PET study. Luna-Reyes I, Pérez-Hernández E, Ávila-Rodríguez MA, Mas-Oliva J. Care Med Exp 2018. https://doi.org/10.1186/s40635-018-0196-z